Edgewise announces completion of EDG-7500 CIRRUS-HCM phase 2 parts B & C and favourable interim safety results from the ongoing part D study in hypertrophic cardiomyopathy ...
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), today announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical ...
Edgewise's EDG-7500 showed clinical activity and a favorable safety profile in Phase 2 trial for hypertrophic cardiomyopathy.
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
Edgewise Therapeutics (EWTX) announced positive updates from the ongoing CIRRUS-HCM, Phase 2 clinical trial of EDG-7500, a novel oral, selective, ...
Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback